科研论文
HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models
ꁲ
Reclinical Pharmacology
characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
H. Ke, T. Yang, F. Zhang, C. Chen, J. Wang, J. Liu, et al.
Sci Rep 2024 Vol. 14 Issue 1 Pages 28201
Accession Number: 39548213 DOI: 10.1038/s41598-024-79865-3
HX008 a humanized PD 1 blocking antibody with potent antitumor activity and superior pharmacologic properties
